FdaApplication
BLA 125549
Identifiers
- fda_app_no: BLA125549
Properties
| Property | Value |
|---|---|
| applicant_name | Wyeth Pharmaceuticals LLC |
| application_type | BLA |
| approval_date | 2014-10-29 |
Revenue by product
TRUMENBA
| Period | Revenue |
|---|---|
| Q4 2023 | $18.0M |
| Q3 2023 | $58.0M |
| Q4 2022 | $15.0M |
| Q3 2022 | $60.0M |
| Q4 2021 | $16.0M |
| Q3 2021 | $52.0M |
| Q4 2020 | $27.0M |
| Q3 2020 | $48.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TRUMENBA | — | 0.5ML | Injection |
1 product